The Trump administration launched a drug pricing initiative offering immediate savings, but experts debated whether lower ...

March 9 (Reuters) - The U.S. health regulator issued a draft guidance on Monday to help drugmakers develop cheaper versions ...

The FDA has proposed new rules to speed up the development of biosimilar drugs, aiming to reduce the costs of biologic ...

The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, ...

With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

As President Donald Trump rolls out his TrumpRx proposal to cut prescription drug prices, economists are raising questions about what happens when prices are capped and whether short-term savings for ...

U.S. drug manufacturers are expected to raise prices on at least 350 medications in 2026. The increase coincides with pressure from the Trump administration to lower consumer costs. The detailed ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Charles River Laboratories ...

Medicare costs could decrease under a new proposal from the Trump administration that would shift the drug payment model entirely. The Centers for Medicare & Medicaid Services (CMS) released details ...